Recent Progress of Nanomedicine and Targeted Drug Delivery for Cancer Treatment

• Other Authors: Zhang, Huijie (Editor)
• Format: Electronic Book Chapter
• Language: English
• Published: Basel MDPI - Multidisciplinary Digital Publishing Institute 2023
• Subjects: Medicine; Pharmacology; graphene quantum dot; targeted drug delivery; photothermal therapy; chemo-therapy; polymeric prodrug; theranostic nanocomplex; pH-triggering releasing; magnetic targeting; magnetic hyperthermia; magnetic resonance imaging; docetaxel; adenosine receptors; PLGA; nanoparticles; lung cancer; Notch signaling; RBPJ protein; drug repurposing; fidaxomicin; acarbose; schaftoside; breast cancer; experimental skin cancer; entrapment efficacy; ethosomes; metformin; in vitro permeation; zeta potential; sesamol; albumin nanoparticles; doxorubicin; oxidative stress; antioxidants; tumor-derived membrane vesicles; cancer therapy; tumor vaccine; personalized immunotherapy; low-density lipoprotein; nanoparticle; tumor microenvironment-responsive; magnetic nanofluid; improved magnetic resonance imaging; neutral-responsive Fenton reaction; enhanced chemodynamic therapy; brain targeting; folate receptor; glioma cancer; erlotinib; blood-brain barrier
• Online Access: DOAB: download the publication; DOAB: description of the publication

Currently, cancer is the second leading cause of death worldwide and is the most complex and challenging disease known to humankind. Due to the complex underlying mechanisms of tumorigenesis and tumor metastasis, as well as the intrinsic limitations of conventional cancer therapies, the effective treatment of cancer remains a great challenge. Novel therapeutic strategies with superior anticancer ability urgently need to be discovered. In recent years, nano-drug delivery systems have been extensively investigated and applied as alternatives to conventional cancer treatments. Cancer nanomedicines aim to achieve the targeted delivery of chemotherapeutic drugs to the tumor site, utilizing strategies such as passive targeting, active targeting and stimuli-triggered drug release, while simultaneously decreasing drug accumulation in normal tissues, which together lead to improved therapeutic efficacy and reduced side effects. Currently, several cancer nanomedicines are in regular use, and several others are in various stages of development.This Special Issue will highlight recent progress in the development of novel nanomedicines and targeted drug delivery systems for cancer therapy.